{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:47:17Z","timestamp":1790765237936,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijtb.2020.09.027","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T22:16:23Z","timestamp":1601763383000},"page":"S69-S78","source":"Crossref","is-referenced-by-count":25,"special_numbering":"S","title":["Adverse drug reactions & drug interactions in MDR-TB patients"],"prefix":"10.1016","volume":"67","author":[{"given":"Amitesh","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekar","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijtb.2020.09.027_bib1","doi-asserted-by":"crossref","first-page":"1701643","DOI":"10.1183\/13993003.01643-2017","article-title":"The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis","volume":"51","author":"Halleux","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ijtb.2020.09.027_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ijtb.2020.09.027_bib3","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","article-title":"Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","author":"Wu","year":"2016","journal-title":"Am J Therapeut"},{"issue":"1","key":"10.1016\/j.ijtb.2020.09.027_bib4","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.061","article-title":"A prospective, observational study of adverse reactions to drug regime for multi-drug resistant pulmonary tuberculosis in central India","volume":"6","author":"Hire","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"10.1016\/j.ijtb.2020.09.027_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijtb.2016.01.031","article-title":"Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis","volume":"63","author":"Prasad","year":"2016","journal-title":"Indian J Tubercul"},{"issue":"6","key":"10.1016\/j.ijtb.2020.09.027_bib6","doi-asserted-by":"crossref","first-page":"1901522","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2020.09.027_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijid.2019.03.036","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: a global feasibility study","volume":"83","author":"Akkerman","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.ijtb.2020.09.027_bib8","first-page":"1382","article-title":"Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative","volume":"8","author":"Nathanson","year":"2004","journal-title":"Int J Tubercul Lung Dis"},{"issue":"suppl 62","key":"10.1016\/j.ijtb.2020.09.027_bib9","article-title":"Nature, Magnitude and risk factors of adverse drug reactions in multidrug resistant tb patients in Eritrea","volume":"52","author":"Russom","year":"2018","journal-title":"Eur Respir J [Internet]"},{"issue":"12","key":"10.1016\/j.ijtb.2020.09.027_bib10","first-page":"1314","article-title":"Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia","volume":"11","author":"Shin","year":"2007","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.ijtb.2020.09.027_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/0970-2113.217569","article-title":"Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study","volume":"34","author":"Dela","year":"2017","journal-title":"Lung India"},{"issue":"10150","key":"10.1016\/j.ijtb.2020.09.027_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijtb.2020.09.027_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijtb.2020.09.027_bib14","series-title":"WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","author":"WHO","year":"2020"},{"key":"10.1016\/j.ijtb.2020.09.027_bib15","series-title":"Tuberculosis [Internet]","article-title":"Adverse anti-tuberculosis drug events and their management","author":"Caminero","year":"2018"},{"issue":"12","key":"10.1016\/j.ijtb.2020.09.027_bib16","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.5588\/ijtld.18.0423","article-title":"QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment","volume":"22","author":"Monedero-Recuero","year":"2018","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.ijtb.2020.09.027_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2215\/CJN.01840506","article-title":"Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis","volume":"1","author":"Czock","year":"2006","journal-title":"CJASN"},{"issue":"3","key":"10.1016\/j.ijtb.2020.09.027_bib18","doi-asserted-by":"crossref","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2020.09.027_bib19","unstructured":"Guide for new TB drugs version 4.0.pdf [Internet]. [cited 2020 Jul 29]. Available from: https:\/\/www.pih.org\/endtb\/sites\/default\/files\/2018-04\/Guide%20for%20New%20TB%20Drugs%20Version%204.0.pdf."},{"key":"10.1016\/j.ijtb.2020.09.027_bib20","series-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis [Internet]","author":"WHO","year":"2020"},{"key":"10.1016\/j.ijtb.2020.09.027_bib21","series-title":"QT Effects of Bedaquiline, Delamanid or Both in MDR-TB Patients: The Deliberate Trial","first-page":"4","author":"Dooley","year":"2019"},{"issue":"suppl 4","key":"10.1016\/j.ijtb.2020.09.027_bib22","first-page":"7","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijtb.2020.09.027_bib23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ijtb.2020.09.027_bib25","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1183\/09031936.00076811","article-title":"Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India","volume":"39","author":"Singla","year":"2012","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ijtb.2020.09.027_bib26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2217\/fmb-2019-0231","article-title":"Clofazimine: an old drug for never-ending diseases","volume":"15","author":"Riccardi","year":"2020","journal-title":"Future Microbiol"},{"issue":"8","key":"10.1016\/j.ijtb.2020.09.027_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis","volume":"17","author":"Gopal","year":"2013","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.ijtb.2020.09.027_bib28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2147\/IDR.S194484","article-title":"Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China","volume":"12","author":"Wang","year":"2019","journal-title":"IDR"},{"issue":"10","key":"10.1016\/j.ijtb.2020.09.027_bib29","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5588\/ijtld.12.0863","article-title":"Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis","volume":"17","author":"Hwang","year":"2013","journal-title":"Int J Tubercul Lung Dis"},{"issue":"11","key":"10.1016\/j.ijtb.2020.09.027_bib30","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.5588\/ijtld.16.0498","article-title":"Carbapenems against Mycobacterium tuberculosis: a review of the evidence","volume":"20","author":"Jaganath","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"issue":"7","key":"10.1016\/j.ijtb.2020.09.027_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ijtb.2020.09.027_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review","volume":"17","author":"Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.ijtb.2020.09.027_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02586-16","article-title":"Adverse effects and choice between the injectable Agents amikacin and capreomycin in multidrug-resistant tuberculosis","volume":"61","author":"Arnold","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijtb.2020.09.027_bib34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1183\/13993003.00438-2016","article-title":"Efficacy and tolerability of ethionamide versus prothionamide: a systematic review","volume":"48","author":"Scardigli","year":"2016","journal-title":"Eur Respir J"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072030175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072030175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T19:01:12Z","timestamp":1607713272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001957072030175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S001957072030175X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2020.09.027","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}